All In Biotech

Drug Trial Radar · NCT03316560

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Confirmed by a Pathogenic Variant in the RPGR Gene

Last checked: Nov 20, 2026Latest source record: May 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

29

Actual

Start

Apr 16, 2018

Primary completion

Nov 9, 2023

Study completion Mar 2025

Sponsor

Lead sponsor
Beacon TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 6 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.

Conditions

  • X-Linked Retinitis Pigmentosa

Interventions

  • rAAV2tYF-GRK1-RPGRBiological

    Adeno-associated virus vector expressing a human RPGR gene

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and proportion of Adverse EventsTime frame: Day 0 - Month 36
  2. Number and proportion of participants experiencing abnormal clinically relevant hematology or clinical chemistry parameters.Time frame: Day 0 - Month 36

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Duke University

    Durham, North Carolina

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • Casey Eye Institute

    Portland, Oregon

  • Retina Foundation of the Southwest

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.